Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366179680> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W4366179680 endingPage "S38" @default.
- W4366179680 startingPage "S38" @default.
- W4366179680 abstract "Vaccines based on recombinant mRNA technology helped to control the pandemic caused by the severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2). Clinical trials for showed that these vaccines are safe and effective and promote a strong type 1 driven T cell response. Yet, several reports claimed that SARS-CoV-2 mRNA vaccination might favor the onset, worsening or the reactivation of autoimmune disorders like pemphigus and bullous pemphigoid. However, no study demonstrated a direct immunological link between mRNA vaccination and disease appearance/worsening. We aimed to analyze the immunological and clinical effects exerted by mRNA booster vaccinations for SARS-CoV-2 in a cohort of patients with pemphigus (n=9), bullous pemphigoid (n=4) and in healthy individuals (n=5). Patients and healthy individuals were monitored at baseline, and after two and four weeks of mRNA vaccination. We assessed the clinical disease status, antibodies against the SARS-CoV-2 spike protein, antibody levels for BP180/230, DSG1/3 and tetanustoxoid. We also determined the distribution of peripheral T helper / T follicular cell subsets, intracellular cytokine production of T cells and cytokine serum levels. Our results show that booster vaccination increased anti spike protein IgG, while tetanustoxoid igC and skin-specific autoantibody titers were not or minimally affected. We observed an increase in Th1/Th17.1 cells, together with an increase in the intracellular production of IFN-γ, IL-4 and IL-21 in peripheral T cells of pemphigus patients. Importantly, clinical activity in both remittent patients and in patients with active disease remained stable. In summary, vaccination with mRNA vaccines induced a specific activation of the humoral system with production of protective antibodies against the Sars-CoV-2 spike protein without affecting autoimmune disease activity in patients with pemphigus and bullous pemphigoid." @default.
- W4366179680 created "2023-04-19" @default.
- W4366179680 creator A5003190915 @default.
- W4366179680 creator A5009364633 @default.
- W4366179680 creator A5011571535 @default.
- W4366179680 creator A5017866709 @default.
- W4366179680 creator A5021766437 @default.
- W4366179680 creator A5021857343 @default.
- W4366179680 creator A5025603389 @default.
- W4366179680 creator A5049836293 @default.
- W4366179680 creator A5073539490 @default.
- W4366179680 creator A5087726084 @default.
- W4366179680 creator A5090526144 @default.
- W4366179680 date "2023-05-01" @default.
- W4366179680 modified "2023-10-01" @default.
- W4366179680 title "219 Clinical and immunological impact of booster immunization with recombinant mRNA vaccines for SARS-CoV-2 in patients with pemphigus and bullous pemphigoid" @default.
- W4366179680 doi "https://doi.org/10.1016/j.jid.2023.03.222" @default.
- W4366179680 hasPublicationYear "2023" @default.
- W4366179680 type Work @default.
- W4366179680 citedByCount "0" @default.
- W4366179680 crossrefType "journal-article" @default.
- W4366179680 hasAuthorship W4366179680A5003190915 @default.
- W4366179680 hasAuthorship W4366179680A5009364633 @default.
- W4366179680 hasAuthorship W4366179680A5011571535 @default.
- W4366179680 hasAuthorship W4366179680A5017866709 @default.
- W4366179680 hasAuthorship W4366179680A5021766437 @default.
- W4366179680 hasAuthorship W4366179680A5021857343 @default.
- W4366179680 hasAuthorship W4366179680A5025603389 @default.
- W4366179680 hasAuthorship W4366179680A5049836293 @default.
- W4366179680 hasAuthorship W4366179680A5073539490 @default.
- W4366179680 hasAuthorship W4366179680A5087726084 @default.
- W4366179680 hasAuthorship W4366179680A5090526144 @default.
- W4366179680 hasBestOaLocation W43661796801 @default.
- W4366179680 hasConcept C159047783 @default.
- W4366179680 hasConcept C159654299 @default.
- W4366179680 hasConcept C163764329 @default.
- W4366179680 hasConcept C203014093 @default.
- W4366179680 hasConcept C22070199 @default.
- W4366179680 hasConcept C2778690821 @default.
- W4366179680 hasConcept C2779252107 @default.
- W4366179680 hasConcept C2781327288 @default.
- W4366179680 hasConcept C71924100 @default.
- W4366179680 hasConceptScore W4366179680C159047783 @default.
- W4366179680 hasConceptScore W4366179680C159654299 @default.
- W4366179680 hasConceptScore W4366179680C163764329 @default.
- W4366179680 hasConceptScore W4366179680C203014093 @default.
- W4366179680 hasConceptScore W4366179680C22070199 @default.
- W4366179680 hasConceptScore W4366179680C2778690821 @default.
- W4366179680 hasConceptScore W4366179680C2779252107 @default.
- W4366179680 hasConceptScore W4366179680C2781327288 @default.
- W4366179680 hasConceptScore W4366179680C71924100 @default.
- W4366179680 hasIssue "5" @default.
- W4366179680 hasLocation W43661796801 @default.
- W4366179680 hasLocation W43661796802 @default.
- W4366179680 hasOpenAccess W4366179680 @default.
- W4366179680 hasPrimaryLocation W43661796801 @default.
- W4366179680 hasRelatedWork W1969425090 @default.
- W4366179680 hasRelatedWork W1976091839 @default.
- W4366179680 hasRelatedWork W2101875571 @default.
- W4366179680 hasRelatedWork W2135902875 @default.
- W4366179680 hasRelatedWork W2317914672 @default.
- W4366179680 hasRelatedWork W2420728863 @default.
- W4366179680 hasRelatedWork W2802999939 @default.
- W4366179680 hasRelatedWork W2950643777 @default.
- W4366179680 hasRelatedWork W4366227066 @default.
- W4366179680 hasRelatedWork W937898933 @default.
- W4366179680 hasVolume "143" @default.
- W4366179680 isParatext "false" @default.
- W4366179680 isRetracted "false" @default.
- W4366179680 workType "article" @default.